Platelet Transfusion in Acute Intracerebral Hemorrhage
Platelet Transfusion in Acute Primary Intracerebral Hemorrhage for Patients on Platelet Inhibitors
- To prove whether use of antiplatelet agents results into a rapid enlargement of hematoma after onset of acute intracerebral hemorrhage.
- To prove the efficacy and safety of platelet transfusion for prevention of hematoma growth in patients who were stricken by acute intracerebral hemorrhage while being on antiplatelet medication.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Hematoma growth is a well-known powerful determinant of mortality and poor outcome after intracerebral hemorrhage.
- Some observations suggest that previous use of antiplatelet agents associates with rapid hematoma enlargement and poor outcome after cerebral hemorrhage.
- Immediate platelet transfusion for such patients may prevent hematoma growth but also cause thromboembolic complications.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Matti E Hillbom, MD, PhD
- Phone Number: 358-8-315-4518
- Email: matti.hillbom@oulu.fi
Study Contact Backup
- Name: Juha T Huhtakangas, MD
- Phone Number: 358-8-315-4032
- Email: juha.huhtakangas@ppshp.fi
Study Locations
-
-
-
Oulu, Finland, 90029 OYS
- Recruiting
- Department of Neurology, Oulu University Hospital
-
Contact:
- Matti E Hillbom, MD, PhD
- Phone Number: 358-8-315-4518
- Email: matti.hillbom@oulu.fi
-
Contact:
- Juha T Huhtakangas, MD
- Phone Number: 358-8-315-4032
- Email: juha.huhtakangas@ppshp.fi
-
Principal Investigator:
- Juha T Huhtakangas, MD
-
Sub-Investigator:
- Tarja T Haapaniemi, MD, PhD
-
Sub-Investigator:
- Sami T Tetri, MD
-
Sub-Investigator:
- Michaela Bode, MD, PhD
-
Sub-Investigator:
- Pertti Saloheimo, MD, PhD
-
Sub-Investigator:
- Eeva-Riitta Savolainen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- being on either aspirin or clopidogrel or a combination of aspirin and dipyridamole
- acute primary ICH
- > 17 years
- admitted within 6 h after onset of ICH
- ICH score < 4
Exclusion Criteria:
- other type of ICH than acute primary intracerebral hemorrhage
- patients who need neurosurgery
- life expectancy less than 3 months due to comorbid disorders
- confirmed malignant disease (cancer)
- confirmed acute myocardial infarction
- hepatitis and/liver cirrhosis
- renal failure
- infectious disease (HIV, endocarditis etc.)
- current or previous hematologic disease
- women of childbearing age if pregnant
- participation in another study within the preceding 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Platelet transfusion
|
Four units of fresh platelets will be infused immediately
|
|
No Intervention: 2
No platelet transfusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Glasgow Outcome Score
Time Frame: 90 days
|
90 days
|
|
Cardiovascular death occurring within the treatment period
Time Frame: 90 days
|
90 days
|
|
Death due to any cause occurring within the treatment period
Time Frame: 90 days
|
90 days
|
|
Acute myocardial infarction
Time Frame: 90 days
|
90 days
|
|
Venous thromboembolism
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Matti E Hillbom, MD, PhD, Oulu University Central Hospital, Department of Neurology
- Study Director: Seppo S Juvela, MD, PhD, Turku University Central Hospital, Department of Neurosurgery
- Principal Investigator: Lauri Soinne, MD, PhD, Helsinki University Central Hospital, Department of Neurology
- Study Director: Olli Häppölä, MD, PhD, Helsinki University Central Hospital
- Principal Investigator: Aimo Rissanen, MD, PhD, Keski-Suomen Keskussairaala
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A-1 EUDRACT 2007-006206-24
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.